Reviewing Phathom Pharmaceuticals (NASDAQ:PHAT) & OS Therapies (NYSE:OSTX)

Phathom Pharmaceuticals (NASDAQ:PHAT) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Phathom Pharmaceuticals and OS Therapies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	0	1	4	1	3.00
OS Therapies	0	0	2	2	3.50

Phathom Pharmaceuticals presently has a consensus target price of $22.17, suggesting a potential upside of 332.94%. OS Therapies has a consensus target price of $17.50, suggesting a potential upside of 1,215.79%. Given OS Therapies’ stronger consensus rating and higher possible upside, analysts clearly believe OS Therapies is more favorable than Phathom Pharmaceuticals.

Earnings & Valuation

This table compares Phathom Pharmaceuticals and OS Therapies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$55.25 million	6.45	-$201.59 million	($5.35)	-0.96
OS Therapies	N/A	N/A	-$7.79 million	N/A	N/A

OS Therapies has lower revenue, but higher earnings than Phathom Pharmaceuticals.

Insider & Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of OS Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Phathom Pharmaceuticals and OS Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-1,292.14%	N/A	-79.57%
OS Therapies	N/A	N/A	-569.57%

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.